Tag Archives: Advanced NSCLC
Dr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLC
Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer
How do Patients with Advanced NSCLC on Daily Steroids Do on Immune Checkpoint Inhibitors? (BMIC-046)
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients with advanced NSCLC on daily steroids while receiving an immune checkpoint inhibitor against PD-1 or PD-L1. (9:06)
Is Chemo the Key to the Best Combination for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook (BMIC-045)
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy in patients with EGFR mutation-positive advanced NSCLC. (12:37)
Small Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042)
Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR mutation-positive patients with high tumor PD-L1 expression, which led to poor outcomes that should cast a long shadow on this approach. (7:11)
IMpower131: What is the Role for the Carbo/Nab-Paclitaxel/Atezolizumab Combination for Advanced Squamous NSCLC? (BMIC-041)
Dr. Jack West summarizes key data from the IMpower131 trial of patients with advanced squamous NSCLC & examines whether the carboplatin/nab-paclitaxel/atezolizumab combination is a strong treatment option in this patient setting. (8:09)
Is Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 Under 1%, & High TMB? New Data from CheckMate 227 (BMIC-040)
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in patients with low PD-L1 and high tumor mutation burden (TMB). (8:56)
KEYNOTE-407: Practice-Changing Positive Trial for Advanced Squamous NSCLC (BMIC-039)
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a significant survival benefit that should change practice in this setting. (9:32)
KEYNOTE-042: Should Pembrolizumab Replace Chemo for a Broader Population of Patients with Advanced NSCLC? (BMIC-038)
Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation in the Plenary Session at ASCO 2018, clinical implications, & whether it should change practice. (11:04)